Fatty acid synthase (FAS) is highly expressed in many kinds of human cancers, 2 including colorectal cancer (CRC), and we have investigated the potential use of FAS 3 inhibitors for chemoprevention of liver metastasis of CRC in mice. Expression of FAS 4 was evaluated in murine CRC cell line Colon 26 and CMT 93. Cerulenin, a natural 5 inhibitor of FAS induced apoptosis in these cell lines. The ability of cerulenin to prevent 6 development of liver metastatic lesion of Colon 26 was evaluated. The numbers and 7 sizes of liver metastatic CRC tumors are significantly reduced by treating mice with 8 cerulenin. Cerulenin treatment is associated with reduced levels of phosphorylated Akt 9 in Colon 26 cells, suggesting that inhibition of this signal transduction pathway might 10 be involved in the chemo preventive activity of this compound. Based on studies in 11 mouse models, inhibiting FAS would be an effective strategy in preventing and 12 retarding growth of liver metastatic tumors of CRC that have high expression of this 13 enzyme. 14 15
Introduction 1
Colorectal cancer (CRC) is one of the most common cancers in the world with 2 more than million new cases (1) . The liver is the commonest site of distant metastasis in 3 CRC, and approximately 50% of patients ultimately develop liver metastasis in the 4 course of CRC. (1, 2) Despite recent advances, systemic chemotherapy for metastatic 5 disease is considered palliative, and we rarely see long-term survivors treated only by 6 chemotherapy. (1) Hepatic resection, the only curative treatment for liver metastasis of 7 CRC, has become the standard treatment, but most cases of liver metastases are 8 inoperable and approximately 50% of the patients treated with hepatectomy have a 9 tumor recurrence in the liver. (3) 10 Fatty acid synthase (FAS) is highly expressed in many human cancers including 11 CRC , (4) (5) (6) (7) and previous studies have shown that cancer cell growth can be suppressed by 12 inhibiting the activity of this enzyme with a natural antibiotic cerulenin, (8) orlistat which 13 is a pancreatic lipase inhibitor developed for obesity treatment , (9) and C75, which is a 14 stable synthetic small-molecule developed specifically for inhibiting FAS. (10) But there 15 are no previous studies in which FAS inhibitors suppress liver metastasis of CRC. 16 The aim of this study extends the investigation of the potential use of a FAS 17 inhibitor for chemoprevention of liver metastasis of CRC in mice. In this study, we 18 examined the effect of cerulenin on the murine CRC cell line, Colon 26 and CMT 93 19 cell proliferation and apoptosis. Then, the effect of cerulenin on the prevention of 20 growth of liver metastasis lesion of Colon 26 was investigated. experiments, treatment with cerulenin at 30 mg/kg was given i.p. at day 1, 4, and 7 after 7 tumor inoculation in cerulenin group. Two murine CRC cell lines, Colon 26 and CMT 93, were used and tested for 10 mycoplasm-free cell lines. All cancer cell lines were subdivided in multiple tubes for 11 stock in liquid nitrogen immediately after possession. All cell lines were subjected to 12 present experiment within 6 months of resuscitation. Stock cultures were grown in high 13 glucose DMEM containing 10% FBS and 1% antibiotics. The cells were grown in 14 growth medium at 37°C in a 95% air, 5% CO 2 -humidified incubator.
15
Cell viability assay 16 To measure the cytotoxicity of cerulenin against these cancer cells, 3×10 3 cells 17 were plated per well onto 96-well plates. Following overnight culture, cerulenin were 18 added at specified concentrations. After 24 hours of incubation, cell viability was 19 measured by the mitochondrial activity in reducing Plates were read at A 450 on a spectrometer. Eight-week-old male BALB/c mice (Clea, Japan), weighing 24-28g were utilized.
2
The mice were kept in a temperature-controlled room on a 12-hour light-dark cycle.
3 They had free access to water and standard chow throughout the experiment. After an 4 acclimation period of at least 7 days, the mice were separated into two groups as 5 follows: control group, mice without any treatment (n=8); and cerulenin group, mice Inc., Tokyo, Japan) for measuring triglyceride, cholesterol, and ALT levels. 
Results

14
Dose-dependent inhibition of proliferation of CRC cell lines by cerulenin 15 We initially determined whether cerulenin treatment led to inhibit CRC cell 16 proliferation. CRC cells were treated with various doses of cerulenin for 24 h, and cell 17 viability was assayed using WST-8 assay ( Figure 1A) and BrdU assay ( Figure 1B) . Cerulenin-induced growth inhibition was found to be statistically significant (p<0.05)
21
(one way ANOVA) in 100, 150, and 200 µM of cerulenin compared to 0 µM.
22
Induction of apoptosis via activation of caspase-dependent pathway by cerulenin 23
In subsequent experiments, we determined the mechanism of the observed CMT 93 cells in 50 to 100 µM (Fig. 2B) .
7
Inhibition of general lipogenesis by cerulenin 8
To investigate the physiological consequences of in vivo inhibition of FAS, we 9 administered cerulenin (30mg/kg body weight every 3 days) to mice by i.p. injection. 10 We observed slight weight loss following treatment with no significant difference in 11 comparison to the control group (Fig. 3) . Serum triglyceride was significantly decreased 12 in the cerulenin group compared to the control group. This suggests general lipogenesis 13 in the liver was reduced by cerulenin ( Fig. 4) . 15 We evaluated the potential effectiveness of cerulenin for metastatic liver tumors 16 of the CRC cell line. Figure 5A showed histological cross sections of livers removed 17 from representative control group and cerulenin groups. Growth reduction of metastatic 18 liver tumors was recognized in the cerulenin group. Figure 5B indicates tumor areas of 19 the liver in both groups. Tumor growth was significantly reduced by cerulenin 20 administration. Figure 5C showed TUNEL staining of liver sections of control group 21 and cerulenin group. In cerulenin group, apoptotic tumor cells were observed in the 22 metastatic liver tumor. (12, 13) The mechanism by which FAS inhibitor 15 decreases Akt activation is still unclear, but one mechanism that is advocated is that 16 fatty acids synthesized by FAS are incorporated into membrane phospholipids, which 17 are known modulators of Akt activation. (14, 15) FAS has a major role in the synthesis of 18 phospholipids. (16) When FAS expression is decreased by the treatment of cerulenin, less 19 fatty acid will be synthesized and less phospholipid will be available. One of the 20 important phospholipid is PIP 3 . PIP 3 binds to Akt and its activating kinase PDK-1 with 21 high affinity, and the phosphorylation of Akt is dependent on PIP 3 . (17) In this study, a Colon 26 is chemically derived colon cancer from BALB/c mice. (19) It is highly 4 metastatic and many researchers use this cell line for study of liver metastasis of CRC in 5 mice. (20) From these reports we used colon 26 for this study. P53 expression of colon 26 6 is not fully understood, but reacts to IFN alpha to increase p53, and induce apoptosis. Many efforts to treat xenograft cancers with cerulenin or its derivative of C75 were 10 reported in ovary, (23) prostate, (24) mesothelioma, (25) breast cancer, (26) and CRC. (27, 28) 11 But there is no study of treatment of liver metastasis of CRC using cerulenin. In this 12 study we report that cerulenin inhibits liver metastasis of CRC in a mouse model. In the 13 prior studies, the use of cerulenin or C75 has been hampered by transient but severe 14 anorexia and weight loss. Therefore, this compound could also limit the use in the 15 clinical setting. (29, 30) Loftus et al (29) reported that cerulenin treatment 60mg/kg daily for 16 7days caused severe weight loss. Pizer ES et al (23) reported that cerulenin treatment 17 80mg/kg/daily for 7 days caused severe weight loss. Uddin S et al (15) reported that C-75 18 treatment 10mg/kg or 20mg/kg twice weekly did not cause severe weight loss. In our 19 experiments we obtained adequate liver metastasis 9 days after tumor injection. We 20 treated cerulenin 10mg/kg or 30mg/kg twice weekly (every 3 days). In our preliminary 21 study cerulenin treatment of 10mg/kg had no effect (data not shown). By treating 22 30mg/kg of cerulenin every 3 days, inhibition of liver metastasis was observed. At this 23 amount, serum triglyceride was significantly decreased in cerulenin group. That means 24 11 FAS was really inhibited in our animal model. But we could not observe significant 1 weight loss in this group compared to control group. This result indicated the amount of 2 cerulenin in our experiment was appropriate for prevention of side effects of FAS 3 inhibitor. We could not promote complete remission of metastatic tumors by cerulenin 4 at this dose and the appropriate dose of cerulenin or other FAS inhibitors needs to be 5 studied. Also, the effect of FAS inhibitors to the chemically induced colon cancer 6 should be evaluated.
14
Inhibition of tumor growth of liver metastasis of CRC by cerulenin
7
One of the reasons for anorexia brought on by cerulenin or C75 is fatty acid 8 oxidation by activating carnitine O palmitoyltransferase 1. (30) In recent years, it was 9 reported that C93, which inhibits FAS but has no significant effect on fatty acid 
